InspireMD/NSPR

$2.20

-2.22%
-
1D1W1MYTD1YMAX

About InspireMD

InspireMD, Inc. is a medical device company. The Company is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). It markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. It is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

Ticker

NSPR

Sector

Healthcare

Trading on

NASDAQ

Industry

Medical Equipment & Supplies

CEO

Marvin Slosman

Employees

65

Headquarters

Tel aviv-yafo, Israel

InspireMD Metrics

BasicAdvanced
$53.25M
Market cap
-
P/E ratio
-$1.08
EPS
0.89
Beta
-
Dividend rate
$53.25M
0.89046
$3.85
$0.96
37.08K
7.335
6.986
-55.1%
-70.01%
-65.08%
8.581
1.255
1.348
20%
54.02%
35.67%

What the Analysts think about InspireMD

Analyst Ratings

Majority rating from 1 analysts.
Buy

Price Targets

Average projection from 1 analyst.
104.55% upside
High $4.50
Low $4.50
$2.20
Current price
$4.50
Average price target

InspireMD Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-317.64% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$1.7M
13.33%
Net income
$-5.4M
5.88%
Profit margin
-317.64%
-6.58%

InspireMD Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 17.95%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.56
-$0.25
-$0.16
-$0.17
-
Expected
-$0.71
-$0.32
-$0.16
-$0.20
-$0.15
Surprise
-22.06%
-20%
-3.23%
-17.95%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for InspireMD stock?

InspireMD (NSPR) has a market cap of $53.25M as of April 17, 2024.

What is the P/E ratio for InspireMD stock?

The price to earnings (P/E) ratio for InspireMD (NSPR) stock is 0 as of April 17, 2024.

Does InspireMD stock pay dividends?

No, InspireMD (NSPR) stock does not pay dividends to its shareholders as of April 17, 2024.

When is the next InspireMD dividend payment date?

InspireMD (NSPR) stock does not pay dividends to its shareholders.

What is the beta indicator for InspireMD?

InspireMD (NSPR) has a beta rating of 0.89. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the InspireMD stock price target?

The target price for InspireMD (NSPR) stock is $4.5, which is 104.55% above the current price of $2.2. This is an average based on projections from 1 analyst, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell InspireMD stock

Buy or sell InspireMD stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing